Time:
Venue: Redeye, Mäster Samuelsgatan 42,
The event will also be accessible through a live webcast.
During the event, the Company will provide an update and review of its strategy and pipeline. The presentations will focus on the unmet medical need, development plans, pre-launch activities and commercialization plans for the investigational drug Emcitate (tiratricol), being developed as a possible treatment for MCT8 deficiency, as well as additional activities to create and enhance long-term shareholder value. Presentations will be made by members of Egetis’ management team and invited key opinion leaders.
A complete agenda and a link to the live webcast will be shared in advance of the event.
Presentations will be held in English.
If you would like to attend the event in person in
© Modular Finance, source